Pacific Horizon: Encouraging Mutations in the Venture Model
• By Chris Morrison
Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks
By Christopher Morrison
Donald Elmer, the interim CEO of Koronis Pharmaceuticals Inc. and the managing general partner of Seattle-based VC Pacific Horizon Ventures, views the world of venture investing much like the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.